DATE REPORT ISSUED: June 24, 2020
ATTENTION: Members, Medical Board of California
SUBJECT: Special Faculty Permit Review Committee Recommendation
STAFF CONTACT: Marina O’Connor, Chief of Licensing

REQUESTED ACTION:

1) Approve the Special Faculty Permit Review Committee’s (SFPRC) recommendation for a Special Faculty Permit (SFP) appointment for Peter James Goadsby, M.D., Ph.D., pursuant to California Business and Professions Code (BPC) section 2168.1(a)(1)(A).

BACKGROUND:

The Medical Board of California (Board) is authorized to issue an SFP to a physician who is academically eminent and meets all the requirements pursuant to BPC section 2168.1.

The SFP authorizes an individual to practice medicine only within the medical school and its affiliated institutions where the SFP holder is providing instruction as part of the medical school's educational program, and for which the medical school has assumed direct responsibility.

The SFPRC is comprised of two Board members, one who is a physician and one who is a public member, and one representative from each of the 11 allopathic medical schools in California. The SFPRC reviews and makes recommendations to the Board regarding the eligibility of the applicants applying pursuant to BPC section 2168.1(c)(1).

At the SFPRC’s June 11, 2020 meeting, the SFPRC reviewed the qualifications of an applicant from the University of California, Los Angeles, (UCLA), David Geffen School of Medicine. Jonathan R. Hiatt, M.D., Vice Dean for Faculty at David Geffen School of Medicine, Professor of Surgery, UCLA, presented UCLA’s request for Dr. Goadsby to receive an SFP. Dr. Hiatt indicated that Dr. Goadsby’s area of expertise is in the field of neurology, specifically the area of migraine headache research and is an acknowledged leader in the field. Dr. Goadsby has developed novel clinical structures, including to treat headaches that will not respond to standard medical therapies. Dr. Goadsby is a premier clinician and scientist responsible for a new class of drugs involving calcitonin gene-related peptide antagonists to treat migraines. Dr. Goadsby developed inpatient units at both the University of California San Francisco (UCSF), School of Medicine and Kings College London, and plans to develop one at UCLA as well.

Dr. Goadsby is currently a Professor of Neurology at UCSF under an SFP approved by the Board in 2007. Additionally, Dr. Goadsby is the Director of the National Institute of Health Research-Wellcome Trust Research Facility and Professor of Neurology at Kings College London. Dr. Goadsby has received more than 50 honors and awards, many of them for clinical care and education, including the 2019 H.G. Wolff M.D. Award by the American Headache Society. Dr. Goadsby is one of the most highly cited
scientists in the world having published over 400 peer-reviewed articles, over 250 reviews, over 150 book chapters, and 11 books.

If approved for an SFP appointment by the Board, Dr. Goadsby will hold a full-time faculty position as Professor of Neurology at David Geffen School of Medicine where he will advise research faculty on scientific directions in laboratory studies and basic science programs in headache and migraine, see patients in the outpatient migraine clinic, build a new inpatient migraine unit at UCLA Santa Monica Hospital, and teach medical school students, residents, and fellows.

EDUCATION:

Medical School

The University of New South Wales
Australia: 1977-1984
Graduated: 1984

Postgraduate Training

Prince Henry/Prince of Wales Hospitals
Australia: 1985-1989

The National Hospital for Neurology and Neurosurgery
United Kingdom: 01/1990-12/1990

SPECIAL FACULTY PERMIT REVIEW COMMITTEE FINDINGS:

The SFPRC recommended approval of Dr. Goadsby for an SFP at UCLA, pursuant to BPC section 2168.1(c)(1).
DATE REPORT ISSUED: June 24, 2020
ATTENTION: Members, Medical Board of California
SUBJECT: Special Faculty Permit Review Committee Recommendation
STAFF CONTACT: Marina O’Connor, Chief of Licensing

REQUESTED ACTION:

1) Approve the Special Faculty Permit Review Committee’s (SFPRC) recommendation for a Special Faculty Permit (SFP) appointment for Juan Carlos Martinez Camarillo, M.D., pursuant to California Business and Professions Code (BPC) section 2168.1(a)(1)(B).

BACKGROUND:

The Medical Board of California (Board) is authorized to issue an SFP to a physician who is academically eminent and meets all the requirements pursuant to BPC section 2168.1.

The SFP authorizes an individual to practice medicine only within the medical school and its affiliated institutions where the SFP holder is providing instruction as part of the medical school’s educational program, and for which the medical school has assumed direct responsibility.

The SFPRC is comprised of two Board members, one who is a physician and one who is a public member, and one representative from each of the 11 allopathic medical schools in California. The SFPRC reviews and makes recommendations to the Board regarding the eligibility of the applicants applying pursuant to BPC section 2168.1(c)(1).

At the SFPRC’s June 11, 2020 meeting, the SFPRC reviewed the qualifications of an applicant from the University of Southern California (USC), Keck School of Medicine. Frank Sinatra, M.D., Assistant Dean for Faculty Development, Professor of Pediatrics, USC, presented USC’s request for Dr. Martinez Camarillo to receive an SFP. Dr. Sinatra indicated that as a research faculty member with USC, Dr. Martinez Camarillo has collaborated in several research projects including two novel therapies for ocular trauma. Dr. Martinez Camarillo’s involvement with research and biomedical projects at USC contributed to the development of new technologies for treating ocular trauma, including a contact lens that accelerates corneal wound healing and a thermoresponsive reversible adhesive used to assist with ocular surgeries. Dr. Martinez Camarillo’s unique expertise and surgical skills in managing complicated and sensitive clinical cases will allow USC to develop and maintain an ocular trauma service for the Department of Ophthalmology.

Dr. Martinez Camarillo is currently a research scientist with the Department of Ophthalmology at USC. Dr. Martinez Camarillo was the 2015 awardee for Excellent Case Presentation at the Salzburg Weill Cornell Seminar in Ophthalmology. In addition to his extensive record of peer-reviewed publications, meeting abstracts, and presentations, Dr. Martinez Camarillo has written a book chapter on removing intraocular lens subluxation, served as section editor for four books on selected topics in
ophthalmology, and serves as a journal reviewer in three peer-reviewed journals. Dr. Martinez Camarillo joined the California Project to Cure Blindness, using stem cells to treat patients with advanced age-related macular degeneration. Dr. Martinez Camarillo was appointed as Medical Director of the Translational Research In Vivo Core Facility, one of three facilities included in the national Institutes of Health P30 Grant.

If approved for an SFP appointment by the Board, Dr. Martinez Camarillo will hold a full-time faculty position as Associate Professor of Clinical Ophthalmology at Keck School of Medicine where he is expected to manage ocular trauma and retinal diseases, including diabetic retinopathy and retinal detachment.

EDUCATION:

Medical School

Universidad La Salle Facultad Mexicana de Medicina
Mexico: 2000-2006
Graduated: 2006

Postgraduate Training

Universidad Nacional Autónoma de Mexico, Instituto Nacional de Rehabilitación
Mexico: 2008-2011

University of Southern California, Doheny Eye Institute
California: 2011-2012

Universidad de Guadalajara, Hospital Civil Fray Antonio Alcalde
Mexico: 2011-2013

SPECIAL FACULTY PERMIT REVIEW COMMITTEE FINDINGS:

The SFPRC recommended approval of Dr. Martinez Camarillo for an SFP at USC, pursuant to BPC section 2168.1(c)(1).